

Agneta Nordberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1122772/publications.pdf>

Version: 2024-02-01

368
papers

33,162
citations

4960

84
h-index

4885

168
g-index

383
all docs

383
docs citations

383
times ranked

23584
citing authors

#	ARTICLE	IF	CITATIONS
1	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2023, 164, 309-324.	3.9	43
2	Description of a European memory clinic cohort undergoing amyloid-PET: The AMYPAD Diagnostic and Patient Management Study. <i>Alzheimer's and Dementia</i> , 2023, 19, 844-856.	0.8	6
3	Development of ¹¹ C-Labeled ASEM Analogues for the Detection of Neuronal Nicotinic Acetylcholine Receptors ($\alpha 7$ -nAChR). <i>ACS Chemical Neuroscience</i> , 2022, 13, 352-362.	3.5	6
4	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
5	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- β positivity. <i>Molecular Psychiatry</i> , 2021, 26, 5864-5874.	7.9	22
6	[¹⁸ F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5875-5887.	7.9	14
7	Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer's disease variants: A β 2PParc and PSEN1D9. <i>Molecular Psychiatry</i> , 2021, 26, 5609-5619.	7.9	16
8	Clinical impact of ¹⁸ F-FDG-PET among memory clinic patients with uncertain diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 612-622.	6.4	16
9	<i>In silico</i> studies of ASEM analogues targeting $\alpha 7$ -nAChR and experimental verification. <i>RSC Advances</i> , 2021, 11, 3942-3951.	3.6	2
10	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2110-2120.	6.4	33
11	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	7.3	27
12	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2086-2096.	6.4	11
13	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	6.4	22
14	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [¹⁸ F]flutemetamol amyloid PET images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2183-2199.	6.4	16
15	Astroglial tracer BU99008 detects multiple binding sites in Alzheimer's disease brain. <i>Molecular Psychiatry</i> , 2021, 26, 5833-5847.	7.9	39
16	In vitro Characterization of the Regional Binding Distribution of Amyloid PET Tracer Florbetaben and the Glia Tracers Deprenyl and PK11195 in Autopsy Alzheimer's Brain Tissue. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1723-1737.	2.6	33
17	Astrocyte Biomarkers in Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.1	70
18	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	10.2	396

#	ARTICLE	IF	CITATIONS
19	Subcortical and Cortical Regions of Amyloid- β Pathology Measured by ^{11}C -PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1613-1624.	2.6	3
20	Cryptic Sites in Tau Fibrils Explain the Preferential Binding of the AV-1451 PET Tracer toward Alzheimer's Tauopathy. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2437-2447.	3.5	24
21	Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3487-3496.	3.5	17
22	Assessment of Tau Pathology as Measured by ^{18}F -THK5317 and ^{18}F -Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 103-117.	2.6	4
23	Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. <i>Molecular Psychiatry</i> , 2021, 26, 5888-5898.	7.9	52
24	Characterization of MK6240, a tau PET tracer, in autopsy brain tissue from Alzheimer's disease cases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1093-1102.	6.4	22
25	Lack of fibrillar amyloid plaques but hypometabolism and astrogliosis in autosomal dominant variant A β PParc Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5471-5471.	7.9	0
26	Author Response: Biological Subtypes of Alzheimer Disease: A Systematic Review and Meta-analysis. <i>Neurology</i> , 2021, 96, 238-238.	1.1	2
27	Amyloid-PET and ^{18}F -FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	10.2	254
28	Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism. <i>Brain Connectivity</i> , 2020, 10, 555-565.	1.7	18
29	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.8	43
30	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , 2020, 2, fcaa192.	3.3	24
31	Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme "A plausible missing link for their association with incidence of dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, 1031-1042.	0.8	32
32	Computational Insight into the Binding Profile of the Second-Generation PET Tracer PI2620 with Tau Fibrils. <i>ACS Chemical Neuroscience</i> , 2020, 11, 900-908.	3.5	29
33	Biological subtypes of Alzheimer disease. <i>Neurology</i> , 2020, 94, 436-448.	1.1	210
34	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020, 94, e2026-e2036.	1.1	42
35	Spatial Normalization of ^{18}F -Flutemetamol PET Images Using an Adaptive Principal-Component Template. <i>Journal of Nuclear Medicine</i> , 2019, 60, 285-291.	5.0	40
36	Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. <i>Neurobiology of Aging</i> , 2019, 82, 40-47.	3.1	7

#	ARTICLE	IF	CITATIONS
37	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	3.6	11
38	CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 239.	2.9	15
39	Homomeric and Heteromeric A β Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 176.	2.9	6
40	Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [18F]THK5317 PET. <i>NeuroImage: Clinical</i> , 2019, 22, 101681.	2.7	2
41	Free Energy Profile for Penetration of Pittsburgh Compound-B into the Amyloid β Fibril. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1783-1790.	3.5	9
42	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019, 15, 1081-1103.	0.8	16
43	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 327-332.	2.4	9
44	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1369-1382.	6.4	74
45	Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1276-1286.	6.4	38
46	Astrocyte Biomarkers in Alzheimer's Disease. <i>Trends in Molecular Medicine</i> , 2019, 25, 77-95.	6.7	203
47	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1152-1163.	6.4	30
48	Tau PET imaging in neurodegenerative tauopathies—still a challenge. <i>Molecular Psychiatry</i> , 2019, 24, 1112-1134.	7.9	409
49	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.8	37
50	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 348-356.	6.4	41
51	Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 232-236.	2.4	86
52	Different Positron Emission Tomography Tau Tracers Bind to Multiple Binding Sites on the Tau Fibril: Insight from Computational Modeling. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1757-1767.	3.5	69
53	Comparative In Vitro and In Vivo Quantifications of Pathologic Tau Deposits and Their Association with Neurodegeneration in Tauopathy Mouse Models. <i>Journal of Nuclear Medicine</i> , 2018, 59, 960-966.	5.0	68
54	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. , 2018, 14, 652-663.		18

#	ARTICLE	IF	CITATIONS
55	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
56	Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. <i>Molecular Psychiatry</i> , 2018, 23, 1666-1673.	7.9	88
57	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
58	The relevance of cerebrospinal fluid β -synuclein levels to sporadic and familial Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 130.	5.2	44
59	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	2.7	11
60	Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1605-1617.	6.4	36
61	The contribution of small vessel disease to subtypes of Alzheimer's disease: a study on cerebrospinal fluid and imaging biomarkers. <i>Neurobiology of Aging</i> , 2018, 70, 18-29.	3.1	48
62	Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 45.	6.2	11
63	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. <i>Methods in Molecular Biology</i> , 2018, 1750, 231-251.	0.9	18
64	Comparability of [¹⁸ F]THK5317 and [¹¹ C]PIB blood flow proxy images with [¹⁸ F]FDG positron emission tomography in Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 740-749.	4.3	46
65	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , 2017, 12, 19.	10.8	220
66	Cortical laminar tau deposits and activated astrocytes in Alzheimer's disease visualised by 3H-THK5117 and 3H-deprenyl autoradiography. <i>Scientific Reports</i> , 2017, 7, 45496.	3.3	44
67	Characterization of the binding mode of the PET tracer [18F]ASEM to a chimera structure of the α 7 nicotinic acetylcholine receptor. <i>RSC Advances</i> , 2017, 7, 19787-19793.	3.6	4
68	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 183-195.	3.1	85
69	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 214-227.	3.1	67
70	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. <i>Alzheimer's and Dementia</i> , 2017, 13, 274-284.	0.8	113
71	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2017, 13, 285-295.	0.8	108
72	Development of [11C]/[3H]THK-5351 – A potential novel carbon-11 tau imaging PET radioligand. <i>Nuclear Medicine and Biology</i> , 2017, 46, 50-53.	0.6	16

#	ARTICLE	IF	CITATIONS
73	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 603-614.	2.6	48
74	Effect of Alzheimer Familial Chromosomal Mutations on the Amyloid Fibril Interaction with Different PET Tracers: Insight from Molecular Modeling Studies. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2655-2666.	3.5	8
75	Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. <i>Brain</i> , 2017, 140, aww339.	7.6	153
76	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	10.2	464
77	Quantitative positron emission tomography in brain research. <i>Brain Research</i> , 2017, 1670, 220-234.	2.2	38
78	Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 419-430.	0.8	31
79	[P2â€³366]: HEADâ€œTOâ€œHEAD <i>in vivo</i> COMPARISON OF TAUâ€œSPECIFIC PET TRACERS IN ALZHEIMER'S DISEASE: [¹¹ C]THK5351 VERSUS [¹¹ C]PBB3 PET IMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P765.	0.8	1
80	[P4â€³274]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES. <i>Alzheimer's and Dementia</i> , 2017, 13, P1390.	0.8	0
81	[ICâ€³Pâ€³016]: INVESTIGATING THE CLINICAL IMPACT OF [¹⁸ F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P19.	0.8	0
82	[ICâ€³Pâ€³178]: HEADâ€œTOâ€œHEAD <i>in vivo</i> COMPARISON OF TAUâ€œSPECIFIC PET TRACERS IN ALZHEIMER'S DISEASE: [¹¹ C]THK5351 VERSUS [¹¹ C]PBB3 PET IMAGING. <i>Alzheimer's and Dementia</i> , 2017, 13, P133.	0.8	2
83	[ICâ€³Pâ€³189]: COMPARISON OF BINDING PROPERTIES OF THK5117, THK5351, PBB3 AND T807 IN AUTOPSIES OF ALZHEIMER DISEASE CASES. <i>Alzheimer's and Dementia</i> , 2017, 13, P139.	0.8	0
84	[P1â€³357]: INVESTIGATING THE CLINICAL IMPACT OF [¹⁸ F]FLUTEMETAMOL PET IN A TERTIARY MEMORY CLINIC SETTING IN PATIENTS WITH UNCERTAIN DIAGNOSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P394.	0.8	0
85	Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 96.	6.2	90
86	Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 30.	6.2	110
87	P3â€³262: TAU PET Imaging in Nonâ€œAlzheimerâ€œ Disease Dementia: a Multimodal Paradigm. <i>Alzheimer's and Dementia</i> , 2016, 12, P932.	0.8	0
88	P1â€³306: Association Between <i>in vivo</i> TAU Deposition Measured Using [¹⁸ F]THK5317 Pet and Cognitive Functions in Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P539.	0.8	0
89	ICâ€³Pâ€³170: <i>in vitro</i> Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic AD Brain in Comparison With Sporadic AD Brain Using 3Hâ€œPIB, 3Hâ€œTHK5117 and 3Hâ€œDeprenyl. <i>Alzheimer's and Dementia</i> , 2016, 12, P124.	0.8	0
90	ICâ€³Pâ€³189: TAU PET Imaging in Nonâ€œAlzheimerâ€œ Disease Dementia: A Multimodal Paradigm. <i>Alzheimer's and Dementia</i> , 2016, 12, P137.	0.8	0

#	ARTICLE	IF	CITATIONS
91	O4-07-03: Longitudinal Changes in Regional Tau Deposition in Alzheimer's Disease and other Tauopathies Measured by [18 F]-TKH5317 Pet in a Multi-Tracer Design. , 2016, 12, P348-P349.		0
92	P1-105: In vitro Characterization of Fibrillar Amyloid, TAU Deposition, and Activated Astrocytes in Arctic Alzheimer's Disease Brain in Comparison With Sporadic Alzheimer's Disease Brain Using 3H-PIB, 3H-THK5117 and 3H-DEPRENYL. Alzheimer's and Dementia, 2016, 12, P442.	0.8	0
93	P4-349: EARLY-PHASE [11C]PIB PET is Comparable to [18F]FDG PET as a Marker of Disease Progression in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P1171.	0.8	0
94	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	7.6	107
95	Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 38.	6.2	48
96	The Culprit Is in the Cave: The Core Sites Explain the Binding Profiles of Amyloid-Specific Tracers. Journal of Physical Chemistry Letters, 2016, 7, 3313-3321.	4.6	35
97	Theoretical study of the binding profile of an allosteric modulator NS-1738 with a chimera structure of the $\alpha 7$ nicotinic acetylcholine receptor. Physical Chemistry Chemical Physics, 2016, 18, 28003-28009.	2.8	6
98	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. Journal of Nuclear Medicine, 2016, 57, 1316-1322.	5.0	161
99	Tracer Kinetic Analysis of [¹⁸ F]-THK5117 as a PET Tracer for Assessing Tau Pathology. Journal of Nuclear Medicine, 2016, 57, 574-581.	5.0	51
100	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain, 2016, 139, 922-936.	7.6	235
101	Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1686-1699.	6.4	114
102	Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology, The, 2016, 15, 455-532.	10.2	1,242
103	Comparison of Early-Phase [¹¹ C]-Deuterium-l-Deprenyl and [¹¹ C]-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. Journal of Nuclear Medicine, 2016, 57, 1071-1077.	5.0	63
104	Amyloid- β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BA β ACs. Brain, 2016, 139, 174-192.	7.6	34
105	Imaging β -amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 362-373.	6.4	34
106	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.1	54
107	IC-P-126: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P86-P86.		0
108	P4-254: Characterization of regional binding of clinical amyloid tracers in autosomal dominant and sporadic Alzheimer's disease brains and their interactions with resveratrol. , 2015, 11, P878-P878.		0

#	ARTICLE	IF	CITATIONS
109	O4-07-05: 18F-(S).THK5117 as a PET tracer for tau pathology in Alzheimer's disease and non-alzheimer's disease dementia. , 2015, 11, P285-P285.		0
110	O1-02-03: Divergent pattern of changes in astrocytosis and fibrillar amyloid plaques as measured by PET in autosomal-dominant and sporadic Alzheimer's disease. , 2015, 11, P127-P127.		0
111	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. Scientific Reports, 2015, 5, 16404.	3.3	110
112	Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. Journal of Alzheimer's Disease, 2015, 47, 661-667.	2.6	14
113	Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic \pm Nicotinic Receptor Drugs. Neural Plasticity, 2015, 2015, 1-13.	2.2	51
114	Prediction of AD dementia by biomarkers following the NIA's and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimer's and Dementia, 2015, 11, 1191-1201.	0.8	71
115	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
116	Towards early diagnosis in Alzheimer disease. Nature Reviews Neurology, 2015, 11, 69-70.	10.1	59
117	Degree of abnormality is associated with rate of change in measures of beta-amyloid, glucose metabolism and cognition in an autopsy-verified Alzheimer's disease case. Neurocase, 2015, 21, 738-747.	0.6	0
118	Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 1077-1088.	2.6	38
119	Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1316-1328.	0.8	50
120	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1492-1506.	6.4	11
121	Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1119-1132.	6.4	121
122	The use of amyloid imaging in clinical praxis: a critical review. Clinical and Translational Imaging, 2015, 3, 7-11.	2.1	5
123	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
124	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
125	Visualization of regional tau deposits using 3H-THK5117 in Alzheimer brain tissue. Acta Neuropathologica Communications, 2015, 3, 40.	5.2	58
126	Investigation of the Binding Profiles of AZD2184 and Thioflavin T with Amyloid- β (1-42) Fibril by Molecular Docking and Molecular Dynamics Methods. Journal of Physical Chemistry B, 2015, 119, 11560-11567.	2.6	48

#	ARTICLE	IF	CITATIONS
127	Molecular imaging of neuroinflammation in Alzheimer's disease. <i>Clinical and Translational Imaging</i> , 2015, 3, 437-447.	2.1	11
128	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer's disease patients and control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 438-446.	6.4	64
129	Glial Asthenia and Functional Paralysis. <i>Neuroscientist</i> , 2015, 21, 552-568.	3.5	87
130	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.8	56
131	Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 691-704.	2.6	7
132	Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2120-2126.	6.4	53
133	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , 2014, 13, 614-629.	10.2	2,657
134	Promising two-photon probes for in vivo detection of β^2 amyloid deposits. <i>Chemical Communications</i> , 2014, 50, 11694-11697.	4.1	25
135	Molecular Imaging in Sporadic Alzheimer's Disease Populations and Those Genetically at Risk. <i>Neurodegenerative Diseases</i> , 2014, 13, 160-162.	1.4	5
136	Pharmacodynamics of Cholinesterase Inhibitors Suggests Add-on Therapy with a Low-Dose Carbamylating Inhibitor in Patients on Long-Term Treatment with Rapidly Reversible Inhibitors. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 423-440.	2.6	20
137	O4-02-05: DIFFERENT TIME COURSE OF ASTROCYTOSIS AND AMYLOID DEPOSITION IN ALZHEIMER'S APPSWE TRANSGENIC MICE: A MULTI-TRACER MICROPET STUDY. , 2014, 10, P253-P253.		1
138	PET Tracers for Beta-Amyloid and Other Proteinopathies. , 2014, , 199-212.		2
139	3H-Deprenyl and 3H-PIB autoradiography show different laminar distributions of astroglia and fibrillar β^2 -amyloid in Alzheimer brain. <i>Journal of Neuroinflammation</i> , 2013, 10, 90.	7.2	54
140	Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2465-2481.	3.1	48
141	A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 104-114.	6.4	170
142	Imaging markers for Alzheimer disease. <i>Neurology</i> , 2013, 81, 487-500.	1.1	204
143	Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. <i>Brain</i> , 2013, 136, 2217-2227.	7.6	111
144	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , 2013, 80, 1048-1056.	1.1	161

#	ARTICLE	IF	CITATIONS
145	Combination of 18F-FDG PET and Cerebrospinal Fluid Biomarkers as a Better Predictor of the Progression to Alzheimer's Disease in Mild Cognitive Impairment Patients. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 929-939.	2.6	48
146	Modulation of $\alpha 7$ Nicotinic Acetylcholine Receptor and Fibrillar Amyloid- $\beta 2$ Interactions in Alzheimer's Disease Brain. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 841-851.	2.6	63
147	Neurotrophic and Neuroprotective Actions of (α)- and (+)-Phenserine, Candidate Drugs for Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e54887.	2.5	50
148	Age-Dependent Neuroplasticity Mechanisms in Alzheimer Tg2576 Mice Following Modulation of Brain Amyloid- $\beta 2$ Levels. <i>PLoS ONE</i> , 2013, 8, e58752.	2.5	36
149	A Review of Butyrylcholinesterase as a Therapeutic Target in the Treatment of Alzheimer's Disease. <i>primary care companion for CNS disorders</i> , The, 2013, 15, .	0.6	221
150	Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by ^{11}C -Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining ^{11}C -Pittsburgh Compound B and ^{18}F -FDG. <i>Journal of Nuclear Medicine</i> , 2012, 53, 37-46.	5.0	354
151	Encapsulated Cell Biodelivery of Nerve Growth Factor to the Basal Forebrain in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 18-28.	1.5	123
152	Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic <i>APOE4</i> mutation carriers. <i>Neurology</i> , 2012, 79, 229-236.	1.1	138
153	Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 198.e1-198.e14.	3.1	135
154	Different $\beta 2$ -amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. <i>Neurobiology of Aging</i> , 2012, 33, 825.e1-825.e13.	3.1	86
155	The use of PIB-PET as a dual pathological and functional biomarker in AD. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 380-385.	3.8	49
156	Apolipoprotein $\mu 4$ Modulates Phenotype of Butyrylcholinesterase in CSF of Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 443-458.	2.6	31
157	$\beta 2$ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219.	6.4	55
158	Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 34.	6.2	43
159	Characterization of the Brain $\beta 2$ -Amyloid Isoform Pattern at Different Ages of Tg2576 Mice. <i>Neurodegenerative Diseases</i> , 2011, 8, 352-363.	1.4	18
160	Biomarkers for Alzheimer's disease therapeutic trials. <i>Progress in Neurobiology</i> , 2011, 95, 579-593.	5.7	119
161	The apolipoprotein E $\mu 4$ allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase. <i>Neurobiology of Aging</i> , 2011, 32, 1236-1248.	3.1	48
162	Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. <i>Neurobiology of Aging</i> , 2011, 32, 1388-1399.	3.1	48

#	ARTICLE	IF	CITATIONS
163	Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. <i>Neurobiology of Aging</i> , 2011, 32, 2320.e15-2320.e32.	3.1	50
164	Long-term Effects of Galantamine Treatment on Brain Functional Activities as Measured by PET in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 109-123.	2.6	50
165	Time Course of Glucose Metabolism in Relation to Cognitive Performance and Postmortem Neuropathology in Met146Val PSEN1 Mutation Carriers. <i>Journal of Alzheimer's Disease</i> , 2011, 24, 495-506.	2.6	30
166	Interview: Imaging in Alzheimer's Disease. <i>Imaging in Medicine</i> , 2011, 3, 389-392.	0.0	0
167	Effect of oxotremorine and sodium pentobarbitone on the pharmacokinetics of intravenous tracer doses of radioactive choline. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 29, 96-98.	2.4	5
168	Functional Interactions of Fibrillar and Oligomeric Amyloid- β^2 with Alpha7 Nicotinic Receptors in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 335-347.	2.6	51
169	Transgenic Mice as a Model for Alzheimers Disease. <i>Current Alzheimer Research</i> , 2011, 8, 818-831.	1.4	30
170	Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. <i>Journal of Lipid Research</i> , 2011, 52, 1004-1010.	4.2	90
171	Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. <i>Brain</i> , 2011, 134, 301-317.	7.6	126
172	Neurotrophic factors promote cholinergic differentiation in human embryonic stem cell-derived neurons. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1476-1484.	3.6	45
173	β^2 -Amyloid 1-42 Oligomers Impair Function of Human Embryonic Stem Cell-Derived Forebrain Cholinergic Neurons. <i>PLoS ONE</i> , 2010, 5, e15600.	2.5	47
174	Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1418-1430.	5.0	63
175	Effect of Huprine X on β^2 -Amyloid, Synaptophysin and β^7 Neuronal Nicotinic Acetylcholine Receptors in the Brain of 3xTg-AD and APP ^{swe} Transgenic Mice. <i>Neurodegenerative Diseases</i> , 2010, 7, 379-388.	1.4	31
176	Amyloid Imaging in Early Detection of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2010, 7, 136-138.	1.4	26
177	The use of PET in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2010, 6, 78-87.	10.1	368
178	The Future: New Methods of Imaging Exploration in Alzheimer's Disease. <i>Frontiers of Neurology and Neuroscience</i> , 2009, 24, 47-53.	2.8	8
179	Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients. <i>Current Alzheimer Research</i> , 2009, 6, 4-14.	1.4	75
180	7. Pharmacological modulation of transmitter activity in Alzheimer brains - an experimental model. <i>Acta Neurologica Scandinavica</i> , 2009, 82, 17-20.	2.1	1

#	ARTICLE	IF	CITATIONS
181	A β (25-35) Attenuated SREBP Level in Nuclear Extracts of Serum-Deprived Human Neuroblastoma Cells. <i>Neurochemical Research</i> , 2009, 34, 845-850.	3.3	2
182	[11C]PIB-amyloid binding and levels of A β 40 and A β 42 in postmortem brain tissue from Alzheimer patients. <i>Neurochemistry International</i> , 2009, 54, 347-357.	3.8	83
183	Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 635-646.	1.5	46
184	In vivo amyloid imaging with PET in frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 100-106.	6.4	154
185	Amyloid plaque imaging in vivo: current achievement and future prospects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 46-50.	6.4	74
186	Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. <i>Annals of Neurology</i> , 2008, 63, 621-631.	5.3	124
187	Amyloid imaging in Alzheimer's disease. <i>Neuropsychologia</i> , 2008, 46, 1636-1641.	1.6	66
188	Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. <i>Neurobiology of Aging</i> , 2008, 29, 168-184.	3.1	61
189	PET imaging of amyloid deposition in patients with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2008, 29, 1456-1465.	3.1	611
190	Neuronal Nicotinic Receptor Deficits in Alzheimer Patients with the Swedish Amyloid Precursor Protein 670/671 Mutation. <i>Journal of Neurochemistry</i> , 2008, 72, 1161-1169.	3.9	57
191	Synergistic effect of apolipoprotein E ϵ 4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 289-298.	1.5	49
192	Unidirectional Influx and Net Accumulation of PIB. <i>Open Neuroimaging Journal</i> , 2008, 2, 114-125.	0.2	53
193	Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12506-12511.	7.1	87
194	Amyloid imaging in Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2007, 20, 398-402.	3.6	87
195	Effects of statins on α 7 nicotinic receptor, cholinesterase and α 7-form of secreted amyloid precursor peptide in SH-SY5Y cells. <i>Neurochemistry International</i> , 2007, 50, 800-806.	3.8	26
196	The consequences of reducing expression of the α 7 nicotinic receptor by RNA interference and of stimulating its activity with an α 7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. <i>Neurochemistry International</i> , 2007, 51, 377-383.	3.8	47
197	Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. <i>Glia</i> , 2007, 55, 385-399.	4.9	129
198	Retinoic acid and nerve growth factor induce differential regulation of nicotinic acetylcholine receptor subunit expression in SN56 cells. <i>Journal of Neuroscience Research</i> , 2007, 85, 504-514.	2.9	10

#	ARTICLE	IF	CITATIONS
199	Changes in brain 11C- α -nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. <i>Psychopharmacology</i> , 2007, 191, 1005-1014.	3.1	57
200	Influence of cholesterol and lovastatin on β -form of secreted amyloid precursor protein and expression of α 7 nicotinic receptor on astrocytes. <i>Neurochemistry International</i> , 2006, 49, 459-465.	3.8	27
201	Expression of the α 7, α 4 and α 3 nicotinic receptor subtype in the brain and adrenal medulla of transgenic mice carrying genes coding for human AChE and β -amyloid. <i>International Journal of Developmental Neuroscience</i> , 2006, 24, 269-273.	1.6	8
202	Emerging biology of the cholinergic system across the spectrum of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2006, 18, S3-S16.	1.0	9
203	Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S12-S18.	1.3	119
204	Feedback Regulation of SREBP and Aromatase in A β (25-35)-Supplemented Human Neuroblastoma Cells. <i>Cellular and Molecular Neurobiology</i> , 2006, 26, 225-235.	3.3	6
205	PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. <i>Psychopharmacology</i> , 2006, 188, 509-520.	3.1	128
206	Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE ϵ 4 allele, in relation to cognitive function and cerebral glucose metabolism. <i>Neurobiology of Disease</i> , 2006, 24, 326-333.	4.4	47
207	Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. <i>Brain</i> , 2006, 129, 2856-2866.	7.6	587
208	Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APP ^{swe}) Transgenic Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 30-36.	2.5	57
209	Visualization of nicotinic and muscarinic receptors in brain by positron emission tomography. , 2006, , 181-190.		3
210	Lovastatin stimulates up-regulation of α 7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the β -form of secreted amyloid precursor protein. <i>Journal of Neuroscience Research</i> , 2005, 82, 531-541.	2.9	24
211	Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the α 7, α 4 and α 2 subunits in response to nanomolar concentrations of the β -amyloid peptide 1-42. <i>Neurochemistry International</i> , 2005, 47, 281-290.	3.8	70
212	Early changes in β levels in the brain of APP ^{swe} transgenic mice—Implication on synaptic density, α 7 neuronal nicotinic acetylcholine- and N-methyl-d-aspartate receptor levels. <i>Molecular and Cellular Neurosciences</i> , 2005, 30, 218-227.	2.2	15
213	High selective expression of α 7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. <i>Experimental Neurology</i> , 2005, 192, 215-225.	4.1	126
214	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 104-111.	8.7	134
215	Different patterns of PIB uptake in AD patients. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S666-S666.	4.3	1
216	Follow-up study of amyloid deposition and glucose metabolism in patients with Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S415-S415.	4.3	0

#	ARTICLE	IF	CITATIONS
217	Functional studies of cholinergic activity in normal and Alzheimer disease states by imaging technique. <i>Progress in Brain Research</i> , 2004, 145, 301-309.	1.4	15
218	Nicotine reduces A β 2 in the brain and cerebral vessels of APPsw mice. <i>European Journal of Neuroscience</i> , 2004, 19, 2703-2710.	2.6	122
219	PET imaging of amyloid in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2004, 3, 519-527.	10.2	418
220	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 1540-1543.	6.4	4
221	Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound β . <i>Annals of Neurology</i> , 2004, 55, 306-319.	5.3	3,777
222	Decreased nicotinic receptors in PC12 cells and rat brains influenced by fluoride toxicity—a mechanism relating to a damage at the level in post-transcription of the receptor genes. <i>Toxicology</i> , 2004, 200, 169-177.	4.2	48
223	Effect of subchronic galantamine treatment on neuronal nicotinic and muscarinic receptor subtypes in transgenic mice overexpressing human acetylcholinesterase. <i>Neuropharmacology</i> , 2004, 47, 558-571.	4.1	13
224	Modulation of dopamine release by the nicotinic agonist epibatidine in the frontal cortex and the nucleus accumbens of naive and chronic nicotine treated rats. <i>Neurochemistry International</i> , 2004, 45, 1049-1055.	3.8	12
225	Selective changes in expression of different nicotinic receptor subtypes in brain and adrenal glands of mice carrying human mutated gene for APP or overexpressing human acetylcholinesterase. <i>International Journal of Developmental Neuroscience</i> , 2004, 22, 545-549.	1.6	11
226	Higher expression of α 7 nicotinic acetylcholine receptors in human fetal compared to adult brain. <i>Developmental Brain Research</i> , 2003, 142, 151-160.	1.7	37
227	Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: Possible mechanism involving lipid peroxidation. <i>Journal of Neuroscience Research</i> , 2003, 71, 397-406.	2.9	23
228	Selective decreases of nicotinic acetylcholine receptors in PC12 cells exposed to fluoride. <i>Toxicology</i> , 2003, 183, 235-242.	4.2	22
229	A critical discussion of the role of neuroimaging in mild cognitive impairment*. <i>Acta Neurologica Scandinavica</i> , 2003, 107, 52-76.	2.1	193
230	Correlation of oxidative stress and the loss of the nicotinic receptor alpha4 subunit in the temporal cortex of patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 2003, 338, 13-16.	2.1	16
231	Neuronal nicotinic and muscarinic receptor subtypes at different ages of transgenic mice overexpressing human acetylcholinesterase. <i>Neuroscience Letters</i> , 2003, 340, 148-152.	2.1	15
232	Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. <i>Neurochemistry International</i> , 2003, 43, 243-249.	3.8	147
233	Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 781-789.	1.0	74
234	Toward an Early Diagnosis and Treatment of Alzheimer's Disease. <i>International Psychogeriatrics</i> , 2003, 15, 223-237.	1.0	22

#	ARTICLE	IF	CITATIONS
235	Smoking during Pregnancy: A Way to Transfer the Addiction to the Next Generation?. <i>Respiration</i> , 2002, 69, 289-293.	2.6	98
236	Selective Nicotinic Receptor Consequences in APPSWE Transgenic Mice. <i>Molecular and Cellular Neurosciences</i> , 2002, 20, 354-365.	2.2	60
237	Elevated levels of A β 1-40 and A β 1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice. <i>Neuroscience Letters</i> , 2002, 328, 269-272.	2.1	19
238	Interaction of a Muscarinic Cholinergic Agonist on Acetylcholine and Dopamine Receptors in the Monkey Brain Studied with Positron Emission Tomography. <i>Dementia and Geriatric Cognitive Disorders</i> , 2002, 13, 199-204.	1.5	3
239	Up-regulation of the inflammatory cytokines IFN- γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice. <i>Journal of Neuroimmunology</i> , 2002, 126, 50-57.	2.3	150
240	Selective changes in the levels of nicotinic acetylcholine receptor protein and of corresponding mRNA species in the brains of patients with Parkinson's disease. <i>Brain Research</i> , 2002, 956, 358-366.	2.2	57
241	Chronic fluoride toxicity decreases the number of nicotinic acetylcholine receptors in rat brain. <i>Neurotoxicology and Teratology</i> , 2002, 24, 751-757.	2.4	54
242	The alpha7 nicotinic receptors in human fetal brain and spinal cord. <i>Journal of Neurochemistry</i> , 2002, 80, 457-465.	3.9	47
243	Chronic nicotine treatment reduces A β amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). <i>Journal of Neurochemistry</i> , 2002, 81, 655-658.	3.9	173
244	Chronic Ethanol Treatment Decreases [3H]Epibatidine and [3H]Nicotine Binding and Differentially Regulates mRNA Levels of Nicotinic Acetylcholine Receptor Subunits Expressed in M10 and SH-SY5Y Neuroblastoma Cells. <i>Journal of Neurochemistry</i> , 2002, 70, 1134-1142.	3.9	29
245	Regulation of Nicotinic Receptor Subtypes Following Chronic Nicotinic Agonist Exposure in M10 and SH-SY5Y Neuroblastoma Cells. <i>Journal of Neurochemistry</i> , 2002, 70, 2028-2037.	3.9	47
246	Upregulation of Neuronal Nicotinic Receptor Subunits α 4, β 2, and α 7 in Transgenic Mice Overexpressing Human Acetylcholinesterase. <i>Journal of Molecular Neuroscience</i> , 2002, 18, 211-222.	2.3	30
247	Functional Activation Studies in Alzheimer Patients and Strategies in Drug Evaluation. <i>Advances in Behavioral Biology</i> , 2002, , 183-186.	0.2	0
248	Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. <i>Biological Psychiatry</i> , 2001, 49, 200-210.	1.3	299
249	Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. <i>Journal of Chemical Neuroanatomy</i> , 2001, 22, 115-126.	2.1	165
250	Expression of nicotinic acetylcholine receptors in human and rat adrenal medulla. <i>Life Sciences</i> , 2001, 70, 577-590.	4.3	34
251	Increased Levels of Tau Protein in SH-SY5Y Cells After Treatment with Cholinesterase Inhibitors and Nicotinic Agonists. <i>Journal of Neurochemistry</i> , 2001, 74, 777-784.	3.9	69
252	Synthesis and Characterization of Binding of 5-[76Br] Bromo-3-[[2(S)-Azetidiny]methoxy]pyridine, a Novel Nicotinic Acetylcholine Receptor Ligand, in Rat Brain. <i>Journal of Neurochemistry</i> , 2001, 73, 1264-1272.	3.9	22

#	ARTICLE	IF	CITATIONS
253	Reduced expression of neuronal nicotinic acetylcholine receptors during the early stages of damage by oxidative stress in PC12 cells. <i>Journal of Neuroscience Research</i> , 2001, 66, 551-558.	2.9	34
254	Early Diagnosis of Alzheimer Disease With Positron Emission Tomography. <i>Alzheimer Disease and Associated Disorders</i> , 2000, 14, S109-S113.	1.3	27
255	Apolipoprotein E ϵ 4 allele has an impact on vascular reactivity in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , 2000, 31, 221-231.	3.0	6
256	Neuroprotection in Alzheimer's disease – new strategies for treatment. <i>Neurotoxicity Research</i> , 2000, 2, 157-165.	2.7	17
257	Preface. <i>Behavioural Brain Research</i> , 2000, 113, 1.	2.2	1
258	Rats exhibiting acute behavioural tolerance to nicotine have more [125 I] α -bungarotoxin binding sites in brain than rats not exhibiting tolerance. <i>Behavioural Brain Research</i> , 2000, 113, 105-115.	2.2	12
259	Development of ligands for in vivo imaging of cerebral nicotinic receptors. <i>Behavioural Brain Research</i> , 2000, 113, 143-157.	2.2	85
260	Neuronal nicotinic receptors in the human brain. <i>Progress in Neurobiology</i> , 2000, 61, 75-111.	5.7	695
261	Influence of lipid peroxidation on the nicotinic acetylcholine receptors in PC12 cells. <i>Neuroscience Letters</i> , 2000, 286, 163-166.	2.1	11
262	Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. <i>Clinical Neurophysiology</i> , 2000, 111, 1817-1824.	1.5	262
263	Decreased Protein Levels of Nicotinic Receptor Subunits in the Hippocampus and Temporal Cortex of Patients with Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 2000, 74, 237-243.	3.9	243
264	In vivo positron emission tomography studies on the novel nicotinic receptor agonist [11 C]MPA compared with [11 C]ABT-418 and (S)-[11 C]nicotine in Rhesus monkeys. <i>Nuclear Medicine and Biology</i> , 1999, 26, 633-640.	0.6	30
265	Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. <i>Molecular Brain Research</i> , 1999, 66, 94-103.	2.3	180
266	A Follow-Up Study of the Family with the Swedish APP 670/671 Alzheimer's Disease Mutation. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 526-533.	1.5	30
267	Decreased protein level of nicotinic receptor α 7 subunit in the frontal cortex from schizophrenic brain. <i>NeuroReport</i> , 1999, 10, 1779-1782.	1.2	273
268	Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by [125 I] α -bungarotoxin. <i>Brain Research</i> , 1998, 801, 143-149.	2.2	92
269	Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. <i>Developmental Brain Research</i> , 1998, 108, 147-160.	1.7	145
270	Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1998, 357, 176-182.	3.0	57

#	ARTICLE	IF	CITATIONS
271	Interaction of the nicotinic agonist (R,S)-3-pyridyl-1-methyl-2-(3-pyridyl)-azetidone (MPA) with nicotinic acetylcholine receptor subtypes expressed in cell lines and rat cortex. <i>Neurochemistry International</i> , 1998, 32, 435-441.	3.8	14
272	Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. <i>Neuroscience Letters</i> , 1998, 254, 85-88.	2.1	50
273	Postnatal changes of nicotinic acetylcholine receptor $\alpha 2$, $\alpha 3$, $\alpha 4$, $\alpha 7$ and $\beta 2$ subunits genes expression in rat brain. <i>International Journal of Developmental Neuroscience</i> , 1998, 16, 507-518.	1.6	113
274	Differential changes of nicotinic receptors in the rat brain following ibotenic acid and 192 IgG saporin lesions of the nucleus basalis magnocellularis. <i>International Journal of Developmental Neuroscience</i> , 1998, 16, 661-668.	1.6	14
275	Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease. <i>Drug Safety</i> , 1998, 19, 465-480.	3.2	295
276	Intracerebroventricular Infusion of Nerve Growth Factor in Three Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 246-257.	1.5	419
277	Long-Term Tacrine Treatment in Three Mild Alzheimer Patients. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 228-237.	1.3	73
278	(S)-(-)-[11C]Nicotine Binding Assessed by PET. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 238-246.	1.3	28
279	Tacrine and donepezil attenuate the neurotoxic effect of $A\beta(25-35)$ in rat PC12 cells. <i>NeuroReport</i> , 1998, 9, 1519-1522.	1.2	89
280	In Vitro Evaluation of ^{11}C -Labeled (<i>S</i>)-Nicotine, (<i>S</i>)-3-Methyl-5-(1-Methyl-2-pyrrolidinyl)isoxazole, and (<i>R,S</i>)-1-Methyl-2-(3-pyridyl)azetidone as Nicotinic Receptor Ligands for Positron Emission Tomography Studies. <i>Journal of Neurochemistry</i> , 1998, 71, 1750-1760.	3.9	18
281	Nicotinic Receptors as a new Target for Treatment of Alzheimer's Disease. <i>Advances in Behavioral Biology</i> , 1998, , 463-468.	0.2	1
282	Regional Brain Distribution and Binding of the Muscarinic Receptor Agonist CI-979 Studied by Positron Emission Tomography in the Monkey. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 259-266.	1.5	6
283	Brain Activation in Young and Older Adults During Implicit and Explicit Retrieval. <i>Journal of Cognitive Neuroscience</i> , 1997, 9, 378-391.	2.3	207
284	Imaging of Nicotinic and Muscarinic Receptors in Alzheimer's Disease: Effect of Tacrine Treatment. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 78-84.	1.5	92
285	Use of carbon-11 nicotine in PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 825-826.	2.1	6
286	Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. <i>Neuroscience Letters</i> , 1997, 232, 37-40.	2.1	40
287	Muscarinic receptor subtypes in subpopulations of human blood mononuclear cells as analyzed by RT-PCR technique. <i>Journal of Neuroimmunology</i> , 1996, 68, 139-144.	2.3	45
288	Steady-State Pharmacokinetics of Tacrine in Long-Term Treatment of Alzheimer Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 1996, 7, 111-117.	1.5	10

#	ARTICLE	IF	CITATIONS
289	Differential co-expression of nicotinic acetylcholine receptor $\hat{1}\pm 4$ and $\hat{1}\pm 2$ subunit genes in various regions of rat brain. <i>NeuroReport</i> , 1996, 7, 1645-1649.	1.2	12
290	Tacrine interacts with an allosteric activator site on $\hat{1}\pm 4\hat{1}\pm 2$ nAChRs in M10 cells. <i>NeuroReport</i> , 1996, 7, 2201-2205.	1.2	37
291	Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors. <i>Brain Research</i> , 1996, 726, 207-212.	2.2	26
292	Apolipoprotein E $\hat{1}\mu 4$ allele, skin vessel reactivity and vascular risk factors in Alzheimer's disease. <i>Archives of Gerontology and Geriatrics</i> , 1996, 22, 223-232.	3.0	1
293	Nicotine deposition and body distribution from a nicotine inhaler and a cigarette studied with positron emission tomography. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 59, 593-594.	4.7	58
294	Epibatidine and ABT 418 reveal selective losses of $\hat{1}\pm 4\hat{1}\pm 2$ nicotinic receptors in Alzheimer brains. <i>NeuroReport</i> , 1995, 6, 2419-2423.	1.2	142
295	Kinetic Analysis of Regional (S)(-)- ^{11}C -Nicotine Binding in Normal and Alzheimer Brains In Vivo Assessment Using Positron Emission Tomography. <i>Alzheimer Disease and Associated Disorders</i> , 1995, 9, 21-27.	1.3	192
296	Regulation of $\hat{1}\pm 4\hat{1}\pm 2$ nicotinic acetylcholine receptors in M10 cells following treatment with nicotinic agents. <i>NeuroReport</i> , 1995, 6, 313-317.	1.2	33
297	Regional deposition of inhaled ^{11}C -nicotine vapor in the human airway as visualized by positron emission tomography*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 309-317.	4.7	104
298	Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease. <i>Behavior Genetics</i> , 1995, 25, 149-159.	2.1	88
299	Role of growth factors in degeneration and regeneration in the central nervous system; clinical experiences with NGF in Parkinson's and Alzheimer's diseases. <i>Journal of Neurology</i> , 1994, 242, S12-S15.	3.6	44
300	Effects of chronic treatment with (+)- and (\hat{a} [~])-nicotine on nicotinic acetylcholine receptors and N-methyl-d-aspartate receptors in rat brain. <i>Brain Research</i> , 1994, 644, 32-39.	2.2	45
301	Human nicotinic receptorsâ€™ Their role in aging and dementia. <i>Neurochemistry International</i> , 1994, 25, 93-97.	3.8	109
302	The competition of (?)-[^3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized preparations of different brain regions of rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1993, 348, 28-34.	3.0	43
303	Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics. <i>Brain Research</i> , 1993, 620, 42-48.	2.2	24
304	Clinical studies in Alzheimer patients with positron emission tomography. <i>Behavioural Brain Research</i> , 1993, 57, 215-224.	2.2	67
305	Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy. <i>Behavioural Brain Research</i> , 1993, 57, 255-261.	2.2	145
306	Coupling of muscarinic receptors to GTP proteins in postmortem human brain â€™ alterations in Alzheimer's disease. <i>Neuroscience Letters</i> , 1993, 150, 39-43.	2.1	65

#	ARTICLE	IF	CITATIONS
307	In Vivo Detection of Neurotransmitter Changes in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1993, 695, 27-33.	3.8	30
308	Tacrine restores cholinergic nicotinic receptors and glucose metabolism in alzheimer patients as visualized by positron emission tomography. <i>Neurobiology of Aging</i> , 1992, 13, 747-758.	3.1	145
309	Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists. <i>Brain Research</i> , 1992, 596, 142-148.	2.2	73
310	Biological markers and the cholinergic hypothesis in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 1992, 85, 54-58.	2.1	47
311	Effect of acute and subchronic nicotine treatment on cortical efflux of [³ H]-aspartate and endogenous GABA in freely moving guinea pigs. <i>British Journal of Pharmacology</i> , 1991, 104, 15-20.	5.4	9
312	Temporal studies of the inhibition of voluntary ethanol intake in the rat induced by intermittent ethanol treatment and some long term neurochemical consequences. <i>Drug and Alcohol Dependence</i> , 1991, 28, 129-144.	3.2	10
313	Neonatal nicotine exposure induces permanent changes in brain nicotinic receptors and behaviour in adult mice. <i>Developmental Brain Research</i> , 1991, 63, 201-207.	1.7	79
314	Chapter 33 New approaches to clinical and postmortem investigations of cholinergic mechanisms. <i>Progress in Brain Research</i> , 1990, 84, 313-320.	1.4	1
315	Chapter 43 Future prospects of research on central cholinergic mechanisms. <i>Progress in Brain Research</i> , 1990, 84, 415-418.	1.4	4
316	Effects of two pyrethroids, bioallethrin and deltamethrin, on subpopulations of muscarinic and nicotinic receptors in the neonatal mouse brain. <i>Toxicology and Applied Pharmacology</i> , 1990, 102, 456-463.	2.8	73
317	Influence of development and aging on nicotinic receptor subtypes in rodent brain. <i>International Journal of Developmental Neuroscience</i> , 1990, 8, 715-721.	1.6	38
318	Tetrahydroaminoacridine induces opposite changes in muscarinic and nicotinic receptors in rat brain. <i>European Journal of Pharmacology</i> , 1990, 186, 301-305.	3.5	22
319	Substance P-like immunoreactivity, choline acetyltransferase activity and cholinergic muscarinic receptors in Alzheimer's disease and multi-infarct dementia. <i>Brain Research</i> , 1990, 521, 329-332.	2.2	63
320	Quantitative autoradiography of nicotinic receptors in large cryosections of human brain hemispheres. <i>Neuroscience Letters</i> , 1989, 101, 247-252.	2.1	51
321	Identification of Gly-Pro-Glu (GPE), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide. <i>Biochemical and Biophysical Research Communications</i> , 1989, 165, 766-771.	2.1	107
322	Chapter 14 Effect of nicotine on the release of acetylcholine and amino acids in the brain. <i>Progress in Brain Research</i> , 1989, 79, 149-155.	1.4	27
323	Long-Term Effects on Biotransformation of Labelled Choline in Different Parts of the Rat Brain Induced by Single Choline Injections. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1988, 62, 69-73.	0.0	3
324	Distribution of nicotinic receptors in human thalamus as visualized by 3H-nicotine and 3H-acetylcholine receptor autoradiography. <i>Journal of Neural Transmission</i> , 1988, 73, 77-83.	2.8	38

#	ARTICLE	IF	CITATIONS
325	Characterization of agonist and antagonist binding to muscarinic cholinergic receptors solubilized from rat cerebral cortex. <i>Journal of Neural Transmission</i> , 1988, 72, 11-18.	2.8	7
326	Relation between voluntary ethanol intake in rats and changes in striatal muscarinic binding sites seen after induction of stable ethanol intake by an intermittent ethanol treatment. <i>Brain Research</i> , 1988, 474, 189-191.	2.2	8
327	Influence of age on effects induced by intermittent ethanol treatment on the ethanol drinking pattern and related neurochemical changes in the rat. <i>Drug and Alcohol Dependence</i> , 1988, 22, 117-128.	3.2	6
328	Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains. <i>Neuroscience Letters</i> , 1988, 86, 317-321.	2.1	88
329	[³ H]Acetylcholine nicotinic recognition sites in human brain: Characterization of agonist binding. <i>Neuroscience Letters</i> , 1987, 83, 298-302.	2.1	24
330	In vitro binding of ³ H-acetylcholine to nicotinic receptors in rodent and human brain. <i>Journal of Neural Transmission</i> , 1987, 69, 3-18.	2.8	13
331	Cholinergic topography in Alzheimer brains: a comparison with changes in the monoaminergic profile. <i>Journal of Neural Transmission</i> , 1987, 69, 19-32.	2.8	20
332	Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type. <i>Neuroscience Letters</i> , 1986, 70, 160-164.	2.1	33
333	Subchronic treatment of rats with nicotine: Effects on tolerance and on [³ H]acetylcholine and [³ H]nicotine binding in the brain. <i>Drug and Alcohol Dependence</i> , 1986, 17, 37-45.	3.2	31
334	Reduced number of [³ H]nicotine and [³ H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. <i>Neuroscience Letters</i> , 1986, 72, 115-120.	2.1	412
335	[³ H]muscimol and [³ H]quinuclidinyl benzilate binding in rat cortex in the abstinence after long-term barbital treatment. <i>Acta Physiologica Scandinavica</i> , 1986, 126, 153-156.	2.2	8
336	Physostigmine restores ³ H-acetylcholine efflux from Alzheimer brain slices to normal level. <i>Journal of Neural Transmission</i> , 1986, 67, 275-285.	2.8	103
337	Comparative Analysis of Nicotine-Like Receptor-Ligand Interactions in Rodent Brain Homogenate. <i>Journal of Neurochemistry</i> , 1985, 45, 24-31.	3.9	69
338	The effect of nicotine and cytisine on ³ H-acetylcholine release from cortical slices of guinea-pig brain. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1985, 331, 293-296.	3.0	63
339	Regional [³ H]acetylcholine and [³ H]nicotine binding in developing mouse brain. <i>International Journal of Developmental Neuroscience</i> , 1985, 3, 667-671.	1.6	36
340	Effect of long-term nicotine treatment on [³ H] nicotine binding sites in the rats brain. <i>Drug and Alcohol Dependence</i> , 1985, 16, 9-17.	3.2	50
341	Modulation of Choline Transport and Acetylcholine Synthesis in Synaptosomes from Different Brain Regions. <i>Acta Pharmacologica Et Toxicologica</i> , 1985, 56, 193-198.	0.0	3
342	Effect of Nicotine on Passive Avoidance Behaviour and Motoric Activity in Mice. <i>Acta Pharmacologica Et Toxicologica</i> , 1985, 56, 337-441.	0.0	38

#	ARTICLE	IF	CITATIONS
343	Different interactions of steric isomers of hexobarbital to muscarinic agonist and antagonist binding sites in brain. <i>Brain Research</i> , 1984, 310, 189-192.	2.2	11
344	Muscarinic binding sites in small homogenates and in autoradiographic sections from rat and human spinal cord. <i>Brain Research</i> , 1984, 300, 327-333.	2.2	30
345	Muscarinic receptor compensation in hippocampus of Alzheimer patients. <i>Journal of Neural Transmission</i> , 1983, 56, 13-19.	2.8	84
346	Biochemical changes in Dementia disorders of Alzheimer type (AD/SDAT). <i>Neurobiology of Aging</i> , 1983, 4, 261-271.	3.1	303
347	Pharmacodynamic Effects of Nicotine and Acetylcholine Biosynthesis in Mouse Brain. <i>Acta Pharmacologica Et Toxicologica</i> , 1983, 52, 341-347.	0.0	12
348	The regulation in vitro of placental release of human chorionic gonadotropin, placental lactogen, and prolactin: Effects of an adrenergic beta-receptor agonist and antagonist. <i>American Journal of Obstetrics and Gynecology</i> , 1982, 143, 444-450.	1.3	23
349	Changes in populations of cholinergic binding sites in brain after chronic exposure to barbital in rats. <i>Brain Research</i> , 1982, 246, 105-112.	2.2	24
350	Tolerance, physical dependence and changes in muscarinic receptor binding sites after chronic ethanol treatment in the rat. <i>Life Sciences</i> , 1982, 31, 277-287.	4.3	24
351	Cholinergic activity in hippocampus in chronic alcoholism. <i>Drug and Alcohol Dependence</i> , 1982, 10, 333-344.	3.2	42
352	Effect of denervation on acetylcholine synthesizing activity and nicotine-like binding sites in rat hind limb muscles. <i>Acta Physiologica Scandinavica</i> , 1982, 114, 345-350.	2.2	9
353	Atropine modulates changes in striatal muscarinic receptor binding sites in barbital abstinence in the rat. <i>Acta Physiologica Scandinavica</i> , 1982, 115, 369-371.	2.2	2
354	Acetylcholine synthesizing activity and nicotinic binding sites in rat hind limb muscles during reinnervation. <i>Acta Physiologica Scandinavica</i> , 1982, 116, 429-435.	2.2	16
355	Cholinergic receptors in human hippocampus-- regional distribution and variance with age. <i>Life Sciences</i> , 1981, 29, 1937-1944.	4.3	105
356	Chronic nicotine exposure in rat: A behavioural and biochemical study of tolerance. <i>Drug and Alcohol Dependence</i> , 1981, 8, 51-60.	3.2	42
357	Changes in cholinergic function in rat brain late in abstinence after chronic barbital treatment. <i>Drug and Alcohol Dependence</i> , 1981, 7, 51-61.	3.2	16
358	Diurnal fluctuation in striatal choline acetyltransferase activity and strain difference in brain protein content of the rat. <i>Acta Physiologica Scandinavica</i> , 1980, 108, 385-388.	2.2	8
359	Increased number of muscarinic binding sites in brain following chronic barbiturate treatment to rat. <i>Life Sciences</i> , 1980, 26, 231-237.	4.3	29
360	REGIONAL BIOSYNTHESIS OF ACETYLCHOLINE IN BRAIN FOLLOWING FORCED ORAL CHRONIC BARBITONE TREATMENT TO RAT. <i>Journal of Neurochemistry</i> , 1979, 32, 371-378.	3.9	22

#	ARTICLE	IF	CITATIONS
361	EFFECT OF OXOTREMORINE ON THE APPARENT REGIONAL TURNOVER OF ACETYLCHOLINE IN MOUSE BRAIN. Journal of Neurochemistry, 1978, 30, 383-389.	3.9	18
362	Regional high affinity synaptosomal transport of choline in mouse brain – Influence of oxotremorine treatment. Life Sciences, 1978, 23, 937-944.	4.3	21
363	Decreased brain weights in rats after long-term barbital treatments. Life Sciences, 1978, 23, 1583-1590.	4.3	19
364	Effect of Sodium Pentobarbital on the Apparent Turnover of Acetylcholine in Different Brain Regions. Acta Physiologica Scandinavica, 1977, 99, 336-344.	2.2	33
365	Effect of oxotremorine on endogenous acetylcholine and on uptake and biotransformation of radioactive choline in discrete regions of mouse brain in vivo. Biochemical Pharmacology, 1976, 25, 135-140.	4.4	19
366	Biosynthesis of Acetylcholine in Different Brain Regions <i>in vivo</i> Following Alternative Methods of Sacrifice by Microwave Irradiation. Acta Physiologica Scandinavica, 1976, 98, 307-317.	2.2	27
367	Brain Functional Imaging in Early and Preclinical Alzheimer's Disease. , 0, , 153-164.		4
368	Imaging and behavior in Parkinson's disease: functional imaging. , 0, , 89-96.		0